The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
Singh, S. et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet https://doi.org/10.1016/S0140-6736(24)00701-3 (2024).
Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 33, 115–154 (2022).
Merola, E. et al. Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when Ki-67 Is ≥10%? Oncologist 26, 294–301 (2021).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968–977 (2016).
Kunz, P. L. et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J. Clin. Oncol. 41, 1359–1369 (2023).
Al-Toubah, T., Pelle, E., Valone, T., Haider, M. & Strosberg, J. R. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J. Natl. Compr. Canc. Netw. 20, 29–36 (2022).
Bodei, L. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur. J. Nucl. Med. Mol. Imaging 42, 5–19 (2015).
Cordero-Hernandez, I. S. et al. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr. Relat. Cancer 31, e230203 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.S. has acted as a consultant of Exelixis, Harpoon Therapeutics and Novartis and has received research funding from ITM, Novartis, Radiomedix and RayzeBio. M.C. has acted as a consultant of AAA, Advanz, Esteve, Harbour Biomedical, Harpoon Therapeutics and Novartis, and has received research funding from Advanz.
Rights and permissions
About this article
Cite this article
Strosberg, J., Cives, M. Is NETTER-2 a practice-changing trial?. Nat Rev Clin Oncol 21, 705–706 (2024). https://doi.org/10.1038/s41571-024-00925-8
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41571-024-00925-8
